Pneumonitis

January 26, 2022

Trial Spotlight: Jarushka Naidoo on the EAQ172 Trial for Steroid-Refractory Pneumonitis

This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
September 14, 2020
Lungs

Now Enrolling: EAQ172 for Treatment of Lung Inflammation in Patients with Any Type of Cancer

This phase II trial by EA's Cancer Control and Survivorship Committee is comparing two promising pneumonitis treatments for patients receiving PD-1/PD-L1 therapy